CG
VRTX icon

Cutler Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Cutler Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200
Closed -$57K – 5300
2022
Q3 		$57K Sell
200
-150
-43% -$43.2K ﹤0.01% 1799
2022
Q2 		$98K Buy
+350
New +$93.7K 0.01% 1457
2022
Q1 		– Sell
-2,040
Closed -$484K – 6125
2021
Q4 		$447K Sell
2,040
-1,610
-44% -$313K 0.02% 809
2021
Q3 		$662K Hold
3,650
– – 0.03% 646
2021
Q2 		$735K Sell
3,650
-1,250
-26% -$261K 0.03% 585
2021
Q1 		$1.05M Buy
+4,900
New +$1.08M 0.05% 420
2020
Q2 		– Sell
-900
Closed -$244K – 4950
2020
Q1 		$214K Sell
900
-2,120
-70% -$486K 0.01% 912
2019
Q4 		$661K Sell
3,020
-900
-23% -$182K 0.04% 357
2019
Q3 		$664K Sell
3,920
-400
-9% -$70.8K 0.06% 286
2019
Q2 		$792K Buy
4,320
+3,800
+731% +$664K 0.07% 233
2019
Q1 		$95K Sell
520
-300
-37% -$55.4K 0.01% 1030
2018
Q4 		$135K Hold
820
– – 0.01% 861
2018
Q3 		$158K Hold
820
– – 0.01% 950
2018
Q2 		$139K Buy
820
+720
+720% +$112K 0.01% 946
2018
Q1 		$16K Sell
100
-27,397
-100% -$4.47M ﹤0.01% 2455
2017
Q4 		$4.12M Sell
27,497
-16,991
-38% -$2.52M 0.17% 73
2017
Q3 		$6.76M Buy
44,488
+30,259
+213% +$4.55M 0.25% 50
2017
Q2 		$1.83M Buy
14,229
+11,204
+370% +$1.35M 0.07% 238
2017
Q1 		$330K Sell
3,025
-17,076
-85% -$1.5M 0.01% 860
2016
Q4 		$1.48M Buy
20,101
+5,340
+36% +$435K 0.05% 278
2016
Q3 		$1.29M Buy
14,761
+13,261
+884% +$1.25M 0.06% 244
2016
Q2 		$129K Sell
1,500
-1,273
-46% -$110K 0.01% 1478
2016
Q1 		$220K Sell
2,773
-5,931
-68% -$536K 0.01% 956
2015
Q4 		$1.09M Buy
+8,704
New +$1.05M 0.06% 315

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cutler Group's VRTX Position: Q4 2022 in Review

Cutler Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 200 shares — an estimated $57K sold.

Cutler Group first reported a position in VRTX in Q4 2015 and held it in 24 quarters. The position peaked at $6.76M in Q3 2017. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • Cutler Group reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 200 Vertex Pharmaceuticals shares in Q4 2022, an estimated $57K.
  • Cutler Group first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 24 quarters.
  • Cutler Group's Vertex Pharmaceuticals position peaked at $6.76M in Q3 2017.
  • 1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.